GARDair.

The world’s first in vitro test for the prediction of chemical respiratory sensitizers

Sensitizing chemicals may induce sensitization of the respiratory tract, leading to symptoms known as occupational asthma.

GARDair, which is based on Artificial Intelligence and Genomics, enables not only development of safe products but also preventative measures – something that has not been feasible before.

There is currently a great need for tests in several different industries. GARDair, which was launched in the autumn of 2018, makes it possible to predict the risk of causing hypersensitivity with high reliability.

Using GARDair, it is possible not only to develop better and safer products, but also to be able to offer employees a safe production and work environment.

Interested in relevant results of your assays?

Our test prices are dependent on the quantity of test items. Please contact us or any of our partners for a quotation and slot reservation.